Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant

LESSONS LEARNED: Fulvestrant is a selective estrogen receptor (ER)‐downregulating antiestrogen that blocks ER transcriptional activity and is approved for ER‐positive breast cancer. Fulvestrant also induces accumulation of insoluble ER and activates an unfolded protein response; proteasome inhibitor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Schwartz, Gary, Shee, Kevin, Romo, Bianca, Marotti, Jonathan, Kisselev, Alexei, Lewis, Lionel, Miller, Todd
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176977/
https://ncbi.nlm.nih.gov/pubmed/33641211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13733
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados